Your browser doesn't support javascript.
loading
Multi-Functional AIE Phototheranostic Agent Enhancing αPD-L1 Response for Oral Squamous Cell Carcinoma Immunotherapy.
Yu, Yuewen; Ni, Zihui; Xu, Yanbin; Zhang, Le; Liu, Yucheng; Zeng, Fanrui; Zhang, Ming; Liu, Laikui; Feng, Guangxue; Tang, Ben Zhong.
Afiliación
  • Yu Y; State Key Laboratory of Luminescent Materials and Devices, Guangdong Provincial. Key Laboratory of Luminescence from Molecular Aggregates, School of Materials Science and Engineering, AIE Institute, South China University of Technology, Guangzhou, 510640, China.
  • Ni Z; State Key Laboratory Cultivation Base of Research, Prevention and Treatment for Oral Diseases, Jiangsu Province Engineering Research Center of Stomatological Translational Medicine, Nanjing Medical University, Nanjing, 210029, China.
  • Xu Y; State Key Laboratory Cultivation Base of Research, Prevention and Treatment for Oral Diseases, Jiangsu Province Engineering Research Center of Stomatological Translational Medicine, Nanjing Medical University, Nanjing, 210029, China.
  • Zhang L; State Key Laboratory of Luminescent Materials and Devices, Guangdong Provincial. Key Laboratory of Luminescence from Molecular Aggregates, School of Materials Science and Engineering, AIE Institute, South China University of Technology, Guangzhou, 510640, China.
  • Liu Y; State Key Laboratory of Luminescent Materials and Devices, Guangdong Provincial. Key Laboratory of Luminescence from Molecular Aggregates, School of Materials Science and Engineering, AIE Institute, South China University of Technology, Guangzhou, 510640, China.
  • Zeng F; State Key Laboratory Cultivation Base of Research, Prevention and Treatment for Oral Diseases, Jiangsu Province Engineering Research Center of Stomatological Translational Medicine, Nanjing Medical University, Nanjing, 210029, China.
  • Zhang M; State Key Laboratory Cultivation Base of Research, Prevention and Treatment for Oral Diseases, Jiangsu Province Engineering Research Center of Stomatological Translational Medicine, Nanjing Medical University, Nanjing, 210029, China.
  • Liu L; State Key Laboratory Cultivation Base of Research, Prevention and Treatment for Oral Diseases, Jiangsu Province Engineering Research Center of Stomatological Translational Medicine, Nanjing Medical University, Nanjing, 210029, China.
  • Feng G; State Key Laboratory of Luminescent Materials and Devices, Guangdong Provincial. Key Laboratory of Luminescence from Molecular Aggregates, School of Materials Science and Engineering, AIE Institute, South China University of Technology, Guangzhou, 510640, China.
  • Tang BZ; School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, China.
Small ; : e2405470, 2024 Sep 16.
Article en En | MEDLINE | ID: mdl-39279594
ABSTRACT
Oral squamous cell carcinoma (OSCC) represents a prevalent head and neck malignancy with surgical intervention as the primary clinical option. Immunotherapy, particularly immune checkpoint blockade (ICB) targeting PD-1/PD-L1 shows great promise but is impeded by the immunosuppressive tumor microenvironment and low PD-L1 expression in OSCC. Herein, the "all-in-one" phototherapeutic nanoparticles (TSD NPs) are reported with balanced reactive oxygen species and photothermal conversion capacity for combined photoimmunotherapy and ICB immunotherapy against OSCC. A novel electron acceptor, 3-(dicyanomethylene)-2,3-dihydrobenzothiophene-1,1-dioxide (DTM), is introduced to develop the phototherapeutic agent with aggregation-induced emission (AIE) feature and NIR-II fluorescence centered at 1000 nm. Benefiting from the AIE feature and the DTM acceptor, the resultant TSD NPs also exhibit strong type I reactive oxygen species (ROS) generation and high photothermal conversion efficiency (45.3%), which can profoundly induce immunogenic cell death (ICD), activate cytotoxic T lymphocytes, and convert the immunosuppressive tumor microenvironment into an immune-supportive one. Additionally, TSD NPs upregulate the PD-L1 expression on OSCC cells, thus enhancing the efficacy of combined treatment with αPD-L1 ICB immunotherapy. This results show that the synergistic treatment of TSD NPs and αPD-L1 effectively eradicates solid OSCC tumors without adverse effects on normal tissues, proving a novel and promising strategy for OSCC management.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Small Asunto de la revista: ENGENHARIA BIOMEDICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Small Asunto de la revista: ENGENHARIA BIOMEDICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Alemania